Pulse Biosciences, Inc (PLSE)
NCM · Healthcare · Medical Instruments & Supplies
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Pulse Biosciences, Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 86K | 264K | 401K |
| Gross Profit | -193K | 4K | 31K | |
| Operating Income | -20.3M | -20.4M | -18.3M | -19.1M |
| Net Income | -19.2M | -19.4M | -17.4M | -18.6M |
| Diluted EPS | $-0.28 | $-0.29 | $-0.26 | $-0.27 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 700K | 0.00 | 0.00 | 350K |
| Gross Profit | -11.2M | 0.00 | 0.00 | -189K |
| Operating Income | -58.1M | -43.6M | -56.3M | -76.9M |
| Net Income | -58.5M | -42.2M | -53.6M | -72.8M |
| Diluted EPS | $-1.69 | $-0.85 | $-0.92 | $-1.08 |